Search research articles
Contact Us
Filters
Showing results (21-30 of 82) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2012
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone
Sachin S Saboo, Fiona Fennessy, Lina Benajiba, et al.
Kidney International Reports
|
December 18, 2023
Clinical Outcomes of Monoclonal Gammopathy of Renal Significance Without Detectable Clones
Maho Terashita, Umut Selamet, Shonali Midha, et al.
Journal of Hematology & Oncology
|
April 19, 2015
The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma
Jee-Yeong Jeong, Michelle S Levine, Nirmalee Abayasekara, et al.
Core Evidence
|
August 10, 2010
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
Paul Richardson, Constantine Mitsiades, Jacob Laubach, et al.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
|
March 2, 2025
Oral plasmacytoma in multiple myeloma patients: report of 18 cases
Lama Alabdulaaly, Maryam Jessri, Nathaniel Treister, et al.
British Journal of Haematology
|
September 26, 2015
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
Allison Rosenthal, Shaji Kumar, Craig Hofmeister, et al.
JAMA Oncology
|
September 16, 2016
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review
Weijuan Li, David Garcia, R Frank Cornell, et al.
Oncology (Williston Park, N.Y.)
|
September 6, 2011
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias
Paul G Richardson, Jacob Laubach, Constantine S Mitsiades, et al.
Mediterranean Journal of Hematology and Infectious Diseases
|
March 19, 2011
The treatment of multiple myeloma patients not eligible for asct
Paul Richardson, Jacob Laubach, Anuj Mahindra, et al.
European Journal of Haematology
|
February 23, 2025
Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma
Shahrier Hossain, Clifton Mo, Sarah Patches, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 82) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2012
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone
Sachin S Saboo, Fiona Fennessy, Lina Benajiba, et al.
Kidney International Reports
|
December 18, 2023
Clinical Outcomes of Monoclonal Gammopathy of Renal Significance Without Detectable Clones
Maho Terashita, Umut Selamet, Shonali Midha, et al.
Journal of Hematology & Oncology
|
April 19, 2015
The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma
Jee-Yeong Jeong, Michelle S Levine, Nirmalee Abayasekara, et al.
Core Evidence
|
August 10, 2010
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
Paul Richardson, Constantine Mitsiades, Jacob Laubach, et al.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
|
March 2, 2025
Oral plasmacytoma in multiple myeloma patients: report of 18 cases
Lama Alabdulaaly, Maryam Jessri, Nathaniel Treister, et al.
British Journal of Haematology
|
September 26, 2015
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
Allison Rosenthal, Shaji Kumar, Craig Hofmeister, et al.
JAMA Oncology
|
September 16, 2016
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review
Weijuan Li, David Garcia, R Frank Cornell, et al.
Oncology (Williston Park, N.Y.)
|
September 6, 2011
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias
Paul G Richardson, Jacob Laubach, Constantine S Mitsiades, et al.
Mediterranean Journal of Hematology and Infectious Diseases
|
March 19, 2011
The treatment of multiple myeloma patients not eligible for asct
Paul Richardson, Jacob Laubach, Anuj Mahindra, et al.
European Journal of Haematology
|
February 23, 2025
Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma
Shahrier Hossain, Clifton Mo, Sarah Patches, et al.
Page
of 9